Jun 3 |
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
|
May 30 |
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
|
May 29 |
CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
|
May 29 |
CareDx to Participate in Upcoming Investor Conferences
|
May 24 |
Top 3 Health Care Stocks That May Crash In May
|
May 16 |
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
|
May 13 |
CareDx cut to market perform by Raymond James over valuation
|
May 11 |
Earnings Update: Here's Why Analysts Just Lifted Their CareDx, Inc (NASDAQ:CDNA) Price Target To US$13.80
|
May 10 |
CareDx Reports Mixed Q1 2024 Results; Raises Annual Revenue Guidance
|
May 10 |
CareDx rises as much as 38%, highest intraday gain in six years
|